Table 1 General Characteristics
Characteristic | Total population (n = 152) | ISH evaluated population (n = 78) |
|---|---|---|
Female sex—no. (%) | 152 (100.0%) | 78 (100.0%) |
Age—year | ||
Median | 53 | 58 |
Range | 23–79 | 23–82 |
Disease status—no. (%) | ||
De novo metastatic disease | 70 (46.1%) | 31 (39.7%) |
Recurrence | 82 (53.9%) | 47 (60.3%) |
Metastatic site—no. (%) | ||
Locally advanced | 21 (13.8%) | 8 (10.2%) |
Bone only | 26 (17.1%) | 13 (16.7%) |
Visceral metastasis | 105 (69.1%) | 57 (73.1%) |
Specific metastatic sites—no. (%) | ||
Liver | 45 (29.6%) | 24 (30.7%) |
Lung | 55 (36.2%) | 31 (39.7%) |
Brain | 9 (5.9%) | 4 (5.1%) |
Hormone receptor status—no. (%) | ||
HR+ (ER+ or PR+) | 71 (46.7%) | 42 (53.8%) |
HR− (ER− and PR−) | 81 (53.3%) | 36 (46.2%) |
HER2 IHC—no. (%) | ||
1+ | 2 (1.3%) | 2 (2.6%) |
2+ | 21 (13.8%) | 21 (26.9%) |
3+ | 129 (84.9%) | 55 (70.5%) |
HER2/CEP17 ratio by ISH | ||
Median | 3.23* | 4.125 |
Range | 1.6–8.89* | 1.6–12.25 |
Prior adjuvant or neoadjuvant therapy among recurred disease—no. (%) | (n = 82) | (n = 47) |
Chemotherapy | 74 (93.7%) | 45 (95.7%) |
Anthracycline | 57 (69.5%) | 33 (70.2%) |
Taxane | 49 (59.8%) | 32 (68.1%) |
Anti-HER2 | 53 (64.6%) | 31 (66.0%) |
Hormonal therapy | 44 (97.8%) | 28 (100.0%) |